Tempus AI, Inc.Opportunity Rank #302(TEM) Intrinsic Value & DCF Analysis (2026)
Current Price
$49.47
Last updated: May 08, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
No change vs previous
Trend Score
As of 2026-05-08
The intrinsic value of Tempus AI, Inc. (TEM) is estimated at $-1.90 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $49.47, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -43.97% long-term growth rate and a 12.40% discount rate, reflecting expected future free cash flow and cost of capital.
The intrinsic value of Tempus AI, Inc. (TEM) is estimated at $-1.90 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $49.47, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -43.97% long-term growth rate and a 12.40% discount rate, reflecting expected future free cash flow and cost of capital.Valuation Details
Capital Efficiency
The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.
Fundamental Details
Narrative Details
Trend Details
Investment Coach
- Price moves to at least a mid-teens discount to fair value
- Sustained improvement in ROIC versus WACC spread
- Meaningful shifts in the narrative trend and fundamental score
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates Tempus AI, Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
Tempus AI, Inc.Healthcare
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.